A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line

<div>PI (FL3 log) versus annexin V (FL1 log) histogram of vehicle-treated (a), ESE-15-ol-treated (b), ITH-47-treated (c), and combination-treated (d) MDA-MB-231 cells after 48 hours of exposure. An increase in the number of cells in apoptosis (early and late stages) was observed in combination-treated cells.</div>

BioMed Research International

fig5

Figure 5

Figure 5: A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line 